Measured Wealth Private Client Group LLC Has $1.24 Million Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Key Points

• Measured Wealth Private Client Group LLC increased its stake in Bristol Myers Squibb by 81.5% in the first quarter, now owning 20,267 shares valued at approximately $1.24 million.
• Bristol Myers Squibb recently reported earnings per share of $1.46 for the last quarter, surpassing analysts' expectations of $1.07, along with revenue of $12.27 billion.
• The company announced a quarterly dividend of $0.62 per share, translating to an annualized yield of 5.4%, with a payout ratio currently at 100%.

Measured Wealth Private Client Group LLC increased its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 81.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,267 shares of the biopharmaceutical company's stock after buying an additional 9,103 shares during the quarter. Measured Wealth Private Client Group LLC's holdings in Bristol Myers Squibb were worth $1,236,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Ameriprise Financial Inc. grew its stake in Bristol Myers Squibb by 59.9% in the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in Bristol Myers Squibb by 701.2% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock valued at $705,309,000 after purchasing an additional 10,913,708 shares during the last quarter. Northern Trust Corp grew its stake in Bristol Myers Squibb by 16.2% in the fourth quarter. Northern Trust Corp now owns 24,658,360 shares of the biopharmaceutical company's stock valued at $1,394,677,000 after purchasing an additional 3,431,248 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Bristol Myers Squibb by 72.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 7,769,227 shares of the biopharmaceutical company's stock valued at $439,427,000 after purchasing an additional 3,275,061 shares during the last quarter. Finally, Capital International Investors grew its stake in Bristol Myers Squibb by 7.5% in the fourth quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock valued at $2,593,940,000 after purchasing an additional 3,218,865 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Trading Down 0.1%

Shares of Bristol Myers Squibb stock traded down $0.04 during trading hours on Monday, reaching $45.91. The stock had a trading volume of 8,663,225 shares, compared to its average volume of 13,566,976. The firm has a 50 day simple moving average of $47.32 and a two-hundred day simple moving average of $51.82. The firm has a market capitalization of $93.45 billion, a price-to-earnings ratio of 18.51, a P/E/G ratio of 2.35 and a beta of 0.36. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 1 year low of $42.96 and a 1 year high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.07 by $0.39. The firm had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. Bristol Myers Squibb's revenue for the quarter was up .6% on a year-over-year basis. During the same period in the previous year, the company posted $2.07 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.4%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is presently 100.00%.

Wall Street Analyst Weigh In

BMY has been the topic of several recent research reports. Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Jefferies Financial Group lowered their price objective on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Wall Street Zen lowered Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Finally, Citigroup lowered their price objective on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research report on Friday, August 1st. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Bristol Myers Squibb currently has a consensus rating of "Hold" and an average target price of $56.38.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.